KRAS and non-small cell lung carcinoma: Patients with KRAS+ NSCLC and bone metastases had a significantly higher RANKL expression and higher RANKL: OPG ratio (p=0.002) compared to patients with KRAS+ NSCLC without bone metastases (p=0.017).